COMPANY

Stingray Therapeutics Inc.

Profile checked Oct 10, 2026

Keywords: oncology Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) Advanced / Metastatic Solid Tumor SR-8541A

Funding and NIH signals

NIH award NIH awarded $1.46M (SBIR Phase II 5R44CA278144-04, continuation, notice Sep 16, 2026). NIH RePORTER 5R44CA278144-04 (Sep 16, 2026)
Evidence (1 event)
- Sep 16, 2026 · NIH RePORTER 5R44CA278144-04
  Organization: STINGRAY THERAPEUTICS, INC.; City/State: HOUSTON, TX; Project number: 5R44CA278144-04; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-16; FY total cost (award amount): 1460952; Administering IC: National Cancer Institute; Project title: A Phase 1-2 clinical program for the teatment of Microsatellite Stable Colorectal Cancer with the combination of SR-8541A, Botensilimab, and Balstilimab; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Sep 16, 2026 Grant Government grant — SBIR: $1.46M (annual award, as published), announced Sep 16, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Aug 13, 2025 Grant Government grant — SBIR: $1.46M (annual award, as published), announced Aug 13, 2025. Agency: NIH/NCI. Source: government award database. source ↗
Nov 20, 2024 Trial start 2: Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) source ↗
Oct 12, 2023 Trial start Phase 1: A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors source ↗

Jul 31, 2027 (ESTIMATED) · 2 · Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) · NCT06589440

Estimated primary completion per ClinicalTrials.gov. Dates move.

Last 2 years.

Sep 16, 2026 Government grant — SBIR: $1.46M (annual award, as published), announced Sep 16, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Aug 13, 2025 Government grant — SBIR: $1.46M (annual award, as published), announced Aug 13, 2025. Agency: NIH/NCI. Source: government award database. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT06589440	Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)	2	Recruiting	Nov 20, 2024	Jul 31, 2027 (estimated)
NCT06063681	A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors	Phase 1	Recruiting	Oct 12, 2023	2025-12 (estimated)

Annual award amounts. Total $2.0M.

Jul 18, 2023 NIH award 5R44CA278144-02 FY2023: $836,231 awarded for that fiscal year; activity R44 (SBIR); PI KAADIGE, MOHAN RAO; recipient as written: STINGRAY THERAPEUTICS, INC., HOUSTON, TX. Development of a potent and selecti source ↗
Sep 15, 2022 NIH award 1R44CA278144-01 FY2022: $1,160,011 awarded for that fiscal year; activity R44 (SBIR); PI KAADIGE, MOHAN RAO; recipient as written: STINGRAY THERAPEUTICS, INC., HOUSTON, TX. Development of a potent and selec source ↗